Regulus Therapeutics Gets $10M From Sanofi-Aventis

La Jolla-based Regulus Therapeutics reports today that it has received $10M in an equity investment from drug maker Sanofi-Aventis. The firm said the investment came as part of its strategic alliance with Sanofi-Aventis, which was signed June 21st. Regulus Therapeutics' other investors include Alnylam Pharmaceuticals and Isis Pharmaceuticals. Regulus Therapeutics said its alliance with Sanofi-Aventis is potentially valued at over $750M, and includes the discovery, development and commercialization of microRNA therapeutics. Regulus said the new, $10M investment represents less than 10 percent of its preferred outstanding shares. More information »